An Oxygen‐Self‐Produced Nanoplatform Based on MnO2 for Relieving Hypoxia

Manganese dioxide ( MnO2) nanoparticles are increasingly recognized for their potential in biomedical applications, particularly in the realm of hypoxic cancer therapy, due to their unique physicochemical characteristics. This investigation introduces a novel, template‐free synthesis strategy. The reducing groups inherent in bovine serum albumin (BSA) facilitate a redox reaction with potassium permanganate (KMnO4), while the abundance of functional groups in BSA is instrumental in the formation of MnO2. The transmission electron microscopy (TEM) analysis has characterized the synthesized MnO2 nanoparticles, termed BM NPs, as spherical particles with a mean diameter of 210 nm and zeta potential of −40.1 mV measured by dynamic light scattering (DLS). The Fourier transform infrared (FT‐IR) spectrum of BM NPs exhibits the characteristic peak of MnO2 at 1113 cm‐1 and 620 cm‐1. Furthermore, the elemental composition of BM NPs has been ascertained through energy‐dispersive X‐ray (EDX) elemental mapping analysis. Though concentration of BM NPs up to 200 μg/mL, the survival rate of 4T1 cells remained approximately 75%. Given that BM NPs at a concentration of 100 µg/mL significantly alleviate cellular hypoxia, the high oxygen‐generating capacity of these nanoparticles is proved, suggesting their suitability as a drug delivery system, especially in the context of hypoxic tumor microenvironments.